{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Ma T"],"pubmed_abstract":["<b>Purpose:</b> To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR2285, the first oral coagulation factor XIa (FXIa) inhibitor developed in China in combination with aspirin, clopidogrel or ticagrelor in healthy subjects. <b>Methods:</b> This study was a single-center, randomized, double-blind, placebo-controlled (only SHR2285) design (NCT04945616). A total of 52 healthy subjects, 29 male and 23 female, were completed in this study. The subjects were divided into three groups: A, B and C, 16 subjects in group A [aspirin + clopidogrel + placebo or SHR2285 200 mg bid (1:3, 4 received placebo and 12 received SHR2285)] 16 subjects in group B [aspirin + clopidogrel + placebo or SHR2285 300 mg bid (1:3, 3 received placebo and 13 received SHR2285)] and 20 subjects "],"journal":["Frontiers in pharmacology"],"pagination":["1027627"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9626527"],"repository":["biostudies-literature"],"pubmed_title":["SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor."],"pmcid":["PMC9626527"],"pubmed_authors":["Ju X","Li J","Dong Y","Huang L","Ma T","Jin Y","Xie P","Zhao Y","Yang Z","Yang Y","Sun R","Fei F","Lin H","Geng Y"],"additional_accession":[]},"is_claimable":false,"name":"SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.","description":"<b>Purpose:</b> To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR2285, the first oral coagulation factor XIa (FXIa) inhibitor developed in China in combination with aspirin, clopidogrel or ticagrelor in healthy subjects. <b>Methods:</b> This study was a single-center, randomized, double-blind, placebo-controlled (only SHR2285) design (NCT04945616). A total of 52 healthy subjects, 29 male and 23 female, were completed in this study. The subjects were divided into three groups: A, B and C, 16 subjects in group A [aspirin + clopidogrel + placebo or SHR2285 200 mg bid (1:3, 4 received placebo and 12 received SHR2285)] 16 subjects in group B [aspirin + clopidogrel + placebo or SHR2285 300 mg bid (1:3, 3 received placebo and 13 received SHR2285)] and 20 subjects ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-21T16:52:01.993Z","creation":"2025-02-19T00:31:53.046Z"},"accession":"S-EPMC9626527","cross_references":{"pubmed":["36339534"],"doi":["10.3389/fphar.2022.1027627"]}}